Pfizer, maker of the blockbuster rheumatoid arthritis biologic Enbrel, has taken generic drug maker Sandoz to court for information on its Enbrel biosimilar, after winning a bid for preliminary discovery against Samsung Biopis to pursue a possible infringement case over the same drug.
Class action puts pressure on Icon for speedy resolution of Opal Tower insurance case
Latest suit claims Macquarie owes $4.8M in underpayments
SNF, BASF resolve remaining patent dispute
Sydney Fish Market developer can eye Norton Rose docs in spat over $2.3M ‘secret commission’
Merlin Diamond creditors seek to shield rights over assets as liquidation looms
Claims of class action explosion don’t add up, new report says
Vocation class action lumbers on with pared claims
‘Mother’ consumers know best: IP Australia shuts down Monster Energy’s trade mark opposition
Monster Energy has lost its opposition to coffee company Vittoria Food & Beverage’s proposed ‘Mothersky’ trade mark, with a delegate of the Trade Marks Office saying the energy drink company’s ‘Mother’ energy drink brand was so strong in the minds of consumers that there was no likelihood of confusion.